
Samsung Bioepis Report Signals Turning Point for US Biosimilars
The US biosimilar market continued its upward trajectory in the first quarter of 2025, driven by a potent combination of regulatory reform and competitive pricing strategies. According to Samsung Bioepis’ Q2 Biosimilar Market Report,1 the FDA's …